Jun. 21, 2017

Novopyxis – The first start-up identified by LEO Science & Tech Hub

LEO Pharma announces an investment in the biotechnology company Novopyxis to support the development of an early-stage drug delivery device designed to increase the penetration of topical treatments in the skin.

The hand-held aerosol device will be clinically tested on people with alopecia, where there is a high need for alternative treatment options to painful steroid injections. Alopecia is an autoimmune disease leading to hair loss from all or some parts of the body, usually the scalp.

Read the press release

News from the hub

Apr. 2018 12 LEO Science & Tech Hub Enters Collaboration with Dina Katabi MIT, CSAIL to Explore the Use of Radio Signals for Quantification of Itch

LEO Science & Tech Hub, the Boston based R&D unit of LEO Pharma, has entered into a collaboration with Dina Katabi and MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL). Together they will explore the potential of the MIT group’s Emerald system to quantify scratching behavior. The Emerald technology uses the reflection of radio signals to measure human […]

Read more
Jan. 2018 05 SID and The LEO Pharma Research Foundation Awards

The Society for Investigative Dermatology (SID) and The LEO Foundation (LF) are pleased to announce a partnership for the IID 2018 Meeting in which a Gold and Silver Award will be presented. The IID 2018 Meeting is a joint Meeting of the European Society for Dermatological Research (ESDR), Japanese Society for Investigative Dermatology (JSID), and the […]

Read more